Vericel Stock Price, News & Analysis

Vericel (NASDAQ:VCEL) reported record third-quarter 2025 results with $67.5M total revenue and MACI revenue up 25% to $55.7M. Gross margin was 73.5%, net income was $5.1M (or $0.10 diluted EPS), and non-GAAP adjusted EBITDA rose 69% to $17.0M (25% of revenue). Operating cash flow was a record $22.1M. Burn care revenue totaled $11.8M (Epicel $10.4M; NexoBrid $1.5M) with NexoBrid quarterly revenue up 38% year-over-year. Cash and investments totaled $185M with no debt. The company reaffirmed 2025 guidance of $272–$276M total revenue and ~74% gross margin.

Vericel (NASDAQ:VCEL) will report its third-quarter 2025 financial results on Thursday, November 6, 2025. Management will host a conference call and live webcast at 8:30 a.m. ET to discuss financial results and business highlights.

Investors can access the live webcast and presentation slides at http://investors.vcel.com/events-presentations. A replay of the webcast will be available until November 6, 2026. Telephone participants may call 800-330-6730 (U.S.) or +1-312-471-1351 (international) and use passcode 476633.

Vericel Corporation (NASDAQ:VCEL), a specialist in advanced therapies for sports medicine and severe burn care, will participate in a fireside chat at the Wells Fargo Healthcare Conference. The presentation is scheduled for September 4, 2025, at 3:45 p.m. ET. Investors can access the webcast through Vericel's investor relations website at investors.vcel.com.

Vericel (NASDAQ:VCEL) reported strong Q2 2025 financial results, with total revenue growing 20% to $63.2 million. The company's flagship product MACI saw revenue growth of 21% to $53.5 million, while Burn Care revenue reached $9.8 million. Notable achievements include a gross margin increase of 400+ basis points to 74% and adjusted EBITDA growth of 112% to $13.4 million.

Key operational highlights include training approximately 600 MACI Arthro surgeons, receiving FDA IND clearance for the MACI Ankle clinical study, and achieving the highest number of Epicel biopsies since 2023. The company maintains a strong financial position with $164 million in cash and investments and no debt, while reaffirming its 2025 guidance for MACI revenue growth in the low 20% range.

Vericel Corporation (NASDAQ:VCEL), a leading provider of advanced therapies for sports medicine and severe burn care, has scheduled its second-quarter 2025 financial results announcement for July 31, 2025.

The company will host a conference call and webcast at 8:30 a.m. ET to discuss financial results and business highlights. Investors can access the live webcast through Vericel's Investor Relations website, with presentation slides available during the call. A replay will be accessible until July 31, 2026.

Vericel Corporation (NASDAQ:VCEL), a specialized company in advanced therapies for sports medicine and severe burn care, has announced its upcoming participation in a fireside chat at the Truist Securities MedTech Conference. The presentation is scheduled for Tuesday, June 17, 2025, at 9:20 a.m. ET. Investors and interested parties can access the webcast through the Investor Relations section of Vericel's website at investors.vcel.com. This conference appearance provides an opportunity for investors to gain insights into Vericel's operations and strategic direction in the medical technology sector.

Vericel Corporation (NASDAQ: VCEL) reported strong Q1 2025 financial results, with total revenue reaching $52.6 million. The company's flagship product MACI achieved record Q1 revenue of $46.3 million, representing 15% growth year-over-year. Burn Care revenue totaled $6.3 million, including $5.0 million from Epicel and $1.3 million from NexoBrid.

Key financial metrics include a gross margin of 69%, net loss of $11.2 million ($0.23 per share), and adjusted EBITDA of $3.2 million. The company maintains a strong financial position with $162 million in cash and investments and no debt. Notably, approximately 400 MACI Arthro surgeons have been trained to date, showing over 30% biopsy growth.

Vericel reaffirmed its 2025 revenue growth guidance of 20-23% and raised profitability guidance, projecting gross margin of 74% and adjusted EBITDA margin of 26%. Q2 2025 total revenue growth is expected to be 22-25%.

Vericel Corporation (NASDAQ:VCEL), a specialized company in advanced therapies for sports medicine and severe burn care, has announced its participation in the upcoming Bank of America Securities 2025 Healthcare Conference. The presentation is scheduled for Wednesday, May 14, 2025, at 12:20 p.m. ET (9:20 a.m. PT). Investors and interested parties can access the presentation webcast through the company's investor relations website at http://investors.vcel.com.

Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care markets, has scheduled its first-quarter 2025 financial results announcement for May 8, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss financial results and business highlights.

Investors can access the live webcast through Vericel's Investor Relations website. Call participants can dial (800) 715-9871 domestically or (646) 307-1963 internationally. Presentation slides will be available on the webcast and investor relations section. A replay will remain accessible on the company website until May 8, 2026.